Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 1:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 247 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Healthy Male and Female Subjects Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Bioavailability, Safety and Tolerability of a Solid Dosage Formulation Relative to a Suspension of JNJ-54175446 in Healthy Male and Female Participants

NCT02930694
View directory record Official record
Conditions
Healthy
Interventions
JNJ-54175446 (capsule), JNJ-54175446 (suspension)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2017 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects

NCT00699777
View directory record Official record
Conditions
Osteoporosis
Interventions
Risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years to 50 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
4
States / cities
Gainesville, Florida • Miramar, Florida • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of Q203 in Normal Healthy Male and Female Volunteers

NCT02858973
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Q203, Placebo
Drug
Lead sponsor
Qurient Co., Ltd.
Industry
Eligibility
19 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 in Fed and Fasted Healthy Male and Female Subjects

NCT03237988
View directory record Official record
Conditions
Healthy Subjects
Interventions
CPI-444 Capsules, CPI-444 Tablets
Drug
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2018 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Ascending Dose to Study the Safety, Tolerability, PK and PD Effects of AEF0117

NCT03443895
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AEF0117 oral capsule, Placebo oral capsule
Drug
Lead sponsor
Aelis Farma
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessing the Safety and Tolerability of a Single IV Dose of AZD9742 in Healthy Elderly Male and Female Subjects

NCT01154621
View directory record Official record
Conditions
Tolerability, Healthy, Elderly
Interventions
AZD9742, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
65 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 3, 2010 · Synced Oct 6, 2026, 1:09 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

AZD6765 Oral Single Ascending Dose/Multiple Ascending Dose (SAD/MAD)

NCT00963365
View directory record Official record
Conditions
Healthy
Interventions
AZD6765
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2014 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function

NCT01240967
View directory record Official record
Conditions
Healthy Volunteers, Patients, Pharmacokinetics, Renal Impairment
Interventions
TC-5214
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Oct 6, 2026, 1:09 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Urinary Vitamin C Loss in Diabetic Subjects

NCT00071526
View directory record Official record
Conditions
Diabetes
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 6, 2026, 1:09 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Nicotinamide Mononucleotide Supplementation for Exercise Tolerance Improvement in Healthy Older Adults

NCT07144527
View directory record Official record
Conditions
Aging, Frailty, Exercise Tolerance, Healthy Male and Female Subjects
Interventions
NMN, betaine, low-dose hydrogen peroxide (EGA), Nicotinamide Mononucleotide (NMN), Placebo
Dietary Supplement
Lead sponsor
Scott Silveira
Other
Eligibility
60 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety, Tolerability, PD and PK Study in Healthy Adults

NCT02211625
View directory record Official record
Conditions
Healthy
Interventions
Open-label TRV734 125 mg, TRV734 blinded, Oxycodone IR 10 mg, Placebo
Drug
Lead sponsor
Trevena Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Relative Bioavailability of NKTR-118 in Three Formulations in Healthy Subjects

NCT01365000
View directory record Official record
Conditions
Healthy
Interventions
NKTR118 Formulation 1, NKTR118 Formulation 2, NKTR118 Formulation 3, NKTR118 Formulation 1a, NKTR118 Formulation 3a
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 6, 2026, 1:09 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of Different Amounts of Tablets of a New and a Marketed Tablet Formulation in Healthy Adults

NCT03137030
View directory record Official record
Conditions
Opioid-Related Disorders, Pain, Acute, Pain, Postoperative
Interventions
GRT7014 - Abuse Deterrend Tablet, Norco 5Mg-325Mg Tablet
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 6, 2026, 1:09 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

GSK1247303 First Time in Human Study

NCT00651079
View directory record Official record
Conditions
Healthy Subjects
Interventions
GSK1247303
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2010 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers to Investigate the Effects of Ketoconazole on the Pharmacokinetics of NKTR-118

NCT01520896
View directory record Official record
Conditions
Bioavailability, Healthy Volunteers, Drug- Drug Interactions
Interventions
NKTR-118, Ketoconazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MTP-131 (Bendavia™) in Healthy Adults

NCT01115920
View directory record Official record
Conditions
Healthy
Interventions
MTP-131 (Bendavia™)
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 18, 2010 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Whether Pharmacokinetic and Pharmacodynamic Interactions Exist Between Metformin and Canagliflozin (JNJ-28431754) in Healthy Volunteers

NCT01756417
View directory record Official record
Conditions
Healthy
Interventions
Metformin, Canagliflozin (JNJ-28431754)
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK Study of Sotagliflozin in Subjects With Hepatic Impairment

NCT02471274
View directory record Official record
Conditions
Hepatic Impairment, Healthy
Interventions
sotagliflozin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
4
States / cities
Lakewood, Colorado • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Open-Label, Single-Dose, Pharmacokinetic and Safety Study of E7080 (24 mg) Administered to Subjects With Mild, Moderate, and Severe Renal Impairment and to Healthy Subjects

NCT02199379
View directory record Official record
Conditions
Renal Impairment, Disease Severity
Interventions
Lenvatinib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 79 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
3
States / cities
Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects

NCT03613649
View directory record Official record
Conditions
Electrocardiogram Repolarisation Abnormality, Gonococcal Infection
Interventions
AZD0914, Moxifloxacin, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment

NCT04154670
View directory record Official record
Conditions
Healthy, Renal Insufficiency
Interventions
MGTA-145
Biological
Lead sponsor
Ensoma
Industry
Eligibility
18 Years to 79 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment

NCT06529796
View directory record Official record
Conditions
Focal Segmental Glomerulosclerosis (FSGS)
Interventions
IXP
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
3
States / cities
Miami, Florida • St. Petersburg, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 6, 2026, 1:09 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of JPH034 in Healthy Adult Participants

NCT07534657
View directory record Official record
Conditions
Health Adult Subjects
Interventions
JPH034, Placebo Control
Drug · Other
Lead sponsor
J-Pharma Co., Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Dilworth, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 6, 2026, 1:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetics of 14-day Multiple Dose Titrations of TS-134 in Healthy Volunteers

NCT03742791
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TS-134, Placebo
Drug
Lead sponsor
Taisho Pharmaceutical R&D Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 6, 2026, 1:09 PM EDT